Single-center Phase 2 Study of PD-1 Inhibitor Combined with DNA Hypomethylation Agent + CAG Regimen in Patients with Relapsed/refractory Acute Myeloid Leukemia.
CANCER IMMUNOLOGY IMMUNOTHERAPY（2023）
Key words
PD-1 inhibitor,DNA hypomethylation agent,Relapse,Refractory acute myeloid leukemia,Immune checkpoint inhibitors,Combination therapy for AML
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined